Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... May 10, 2019 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored July 16, 2021 Load more HOT NEWS Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... Embracing Lung Cancer Survivorship I Received the COVID-19 Vaccine – Now What? First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone...
